Renaissance Technologies LLC Sells 39,800 Shares of AngioDynamics, Inc. $ANGO

Renaissance Technologies LLC lessened its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 4.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 803,283 shares of the medical instruments supplier’s stock after selling 39,800 shares during the quarter. Renaissance Technologies LLC owned 1.94% of AngioDynamics worth $9,133,000 at the end of the most recent reporting period.

Other institutional investors have also bought and sold shares of the company. D.A. Davidson & CO. acquired a new position in AngioDynamics during the fourth quarter worth $1,751,000. Weber Capital Management LLC ADV acquired a new stake in shares of AngioDynamics in the 4th quarter valued at $17,978,000. Armistice Capital LLC boosted its stake in shares of AngioDynamics by 3.9% in the 4th quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock valued at $21,828,000 after purchasing an additional 64,000 shares in the last quarter. Bastion Asset Management Inc. grew its holdings in shares of AngioDynamics by 17.4% in the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock worth $14,107,000 after purchasing an additional 194,822 shares during the last quarter. Finally, Royce & Associates LP increased its position in shares of AngioDynamics by 27.3% during the 4th quarter. Royce & Associates LP now owns 1,267,451 shares of the medical instruments supplier’s stock worth $16,274,000 after purchasing an additional 272,091 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on ANGO. HC Wainwright boosted their price target on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Zacks Research cut shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. Canaccord Genuity Group raised their price target on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $19.50.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the firm’s stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $14.72, for a total value of $344,006.40. Following the transaction, the senior vice president directly owned 64,745 shares in the company, valued at $953,046.40. This trade represents a 26.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.00% of the stock is currently owned by company insiders.

AngioDynamics Price Performance

Shares of NASDAQ:ANGO opened at $14.79 on Monday. The stock has a market cap of $611.27 million, a price-to-earnings ratio of -17.00 and a beta of 0.33. The company has a 50 day moving average of $12.81 and a 200-day moving average of $11.51. AngioDynamics, Inc. has a one year low of $8.36 and a one year high of $15.19.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Equities research analysts anticipate that AngioDynamics, Inc. will post -0.27 earnings per share for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.